Emerging data suggest Retatru tide , a dual agonist targeting both incretin and GIP , may provide a significant advancement for body loss . Initial clinical tests have shown substantial losses in abdominal tissue, possibly exceeding current weight-loss therapies . Despite this, additional assessm… Read More